DOC2B

Summary

DOC2B (double C2 domain beta, HGNC:2986) is a protein-coding gene on chromosome 17p13.3, encoding Double C2-like domain-containing protein beta (Q14184). Calcium sensor which positively regulates SNARE-dependent fusion of vesicles with membranes.

There are at least two protein isoforms of the Double C2 protein, namely alpha (DOC2A) and beta (DOC2B), which contain two C2-like domains. DOC2A and DOC2B are encoded by different genes; these genes are at times confused with the unrelated DAB2 gene which was initially named DOC-2. DOC2B is expressed ubiquitously and is suggested to be involved in Ca(2+)-dependent intracellular vesicle trafficking in various types of cells.

Source: NCBI Gene 8447 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 68 total
• MANE Select transcript: NM_003585

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2986
Approved symbol	DOC2B
Name	double C2 domain beta
Location	17p13.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000272636
Ensembl biotype	protein_coding
OMIM	604568
Entrez	8447

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000343572, ENST00000609727, ENST00000613549, ENST00000697390, ENST00000930528, ENST00000952977

RefSeq mRNA: 1 — MANE Select: NM_003585 NM_003585

CCDS: CCDS73934

Canonical transcript exons

ENST00000496357 — 0 exons

Expression profiles

Bgee: expression breadth ubiquitous, 131 present calls, max score 93.35.

FANTOM5 (CAGE): breadth broad, TPM avg 6.6634 / max 475.9939, expressed in 697 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
163593	5.0674	540
163592	1.2034	346
163591	0.2080	102
163590	0.1845	121

Top tissues by expression

132 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	93.35	gold quality
cerebellum	UBERON:0002037	92.87	gold quality
cerebellar cortex	UBERON:0002129	92.85	gold quality
cerebellar hemisphere	UBERON:0002245	92.81	gold quality
cortical plate	UBERON:0005343	91.70	gold quality
nucleus accumbens	UBERON:0001882	87.85	gold quality
Ammon’s horn	UBERON:0001954	87.56	gold quality
anterior cingulate cortex	UBERON:0009835	86.83	gold quality
putamen	UBERON:0001874	85.79	gold quality
right frontal lobe	UBERON:0002810	84.94	gold quality
subcutaneous adipose tissue	UBERON:0002190	84.78	gold quality
superior frontal gyrus	UBERON:0002661	84.60	gold quality
adipose tissue	UBERON:0001013	84.15	gold quality
cerebral cortex	UBERON:0000956	84.04	gold quality
brain	UBERON:0000955	83.99	gold quality
frontal cortex	UBERON:0001870	83.68	gold quality
omental fat pad	UBERON:0010414	83.48	gold quality
caudate nucleus	UBERON:0001873	83.07	gold quality
temporal lobe	UBERON:0001871	82.94	gold quality
hypothalamus	UBERON:0001898	82.92	gold quality
amygdala	UBERON:0001876	82.88	gold quality
prefrontal cortex	UBERON:0000451	82.78	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	82.63	gold quality
Brodmann (1909) area 9	UBERON:0013540	80.91	gold quality
esophagus mucosa	UBERON:0002469	79.96	gold quality
thoracic mammary gland	UBERON:0005200	79.57	gold quality
apex of heart	UBERON:0002098	78.52	gold quality
body of pancreas	UBERON:0001150	77.66	gold quality
mucosa of stomach	UBERON:0001199	77.45	gold quality
esophagus	UBERON:0001043	77.37	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.34

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

19 targeting DOC2B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-6833-5P	99.50	68.93	1161
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-6744-3P	99.22	64.41	972
HSA-MIR-6510-5P	99.14	66.59	1081
HSA-MIR-4757-5P	99.12	64.51	981
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-7113-3P	98.75	65.71	1120
HSA-MIR-5589-5P	98.34	64.82	1148
HSA-MIR-3665	97.73	65.08	975
HSA-MIR-296-5P	97.61	64.02	851
HSA-MIR-1226-5P	96.50	65.28	643
HSA-MIR-635	96.00	65.54	687
HSA-MIR-6774-5P	95.94	65.18	722
HSA-MIR-1268A	87.06	61.46	145
HSA-MIR-1268B	87.06	61.46	145

Literature-anchored findings (GeneRIF, showing 5)

• Study analyzed Doc2alpha and Doc2beta and found that Doc2 responds to changes in [Ca2+], with markedly slower kinetics as compared to the cytosolic domain of syt I (syt), and operates on a timescale consistent with asynchronous neurotransmitter release. (PMID:22036572)
• promoter hypermethylation and silencing of the DOC2B gene is an early and frequent event during cervical carcinogenesis and whose reduced expression due to DNA promoter methylation may lead to selective cervical tumor growth (PMID:24570007)
• Here the authors report that analogous ring-like oligomers assemble from the C2AB domains of other Syt isoforms (Syt2, Syt7, Syt9) as well as related C2 domain containing protein, Doc2B and extended Synaptotagmins (E-Syts). (PMID:27434670)
• Reduction of DOC2B is an early feature of T1 diabetes (T1D), and DOC2B abundance may serve as a valuable in vivo indicator of beta-cell mass and an early biomarker of T1D. (PMID:29506054)
• Double C-2 like domain beta (DOC2B) induces calcium dependent oxidative stress to promote lipotoxicity and mitochondrial dysfunction for its tumor suppressive function. (PMID:36913987)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	doc2b	ENSDARG00000088293
mus_musculus	Doc2b	ENSMUSG00000020848
rattus_norvegicus	Doc2b	ENSRNOG00000060054

Paralogs (31): SYT7 (ENSG00000011347), SYT13 (ENSG00000019505), SYT1 (ENSG00000067715), RPH3A (ENSG00000089169), SYTL4 (ENSG00000102362), SYT17 (ENSG00000103528), SYT10 (ENSG00000110975), SYT5 (ENSG00000129990), SYT11 (ENSG00000132718), SYT4 (ENSG00000132872), SYT6 (ENSG00000134207), SYTL2 (ENSG00000137501), SYT16 (ENSG00000139973), SYTL1 (ENSG00000142765), SYT14 (ENSG00000143469), SYT2 (ENSG00000143858), SYTL5 (ENSG00000147041), SYT8 (ENSG00000149043), DOC2A (ENSG00000149927), SYTL3 (ENSG00000164674), TC2N (ENSG00000165929), SYT9 (ENSG00000170743), SYT12 (ENSG00000173227), RPH3AL (ENSG00000181031), C2CD4C (ENSG00000183186), C2CD4A (ENSG00000198535), SYT15 (ENSG00000204176), C2CD4B (ENSG00000205502), SYT3 (ENSG00000213023), C2CD4D (ENSG00000225556), SYT15B (ENSG00000277758)

Protein

Protein identifiers

Double C2-like domain-containing protein beta — Q14184 (reviewed: Q14184)

All UniProt accessions (2): A0A8V8TML1, Q14184

UniProt curated annotations — full annotation on UniProt →

Function. Calcium sensor which positively regulates SNARE-dependent fusion of vesicles with membranes. Binds phospholipids in a calcium-dependent manner and may act at the priming stage of fusion by modifying membrane curvature to stimulate fusion. Involved in calcium-triggered exocytosis in chromaffin cells and calcium-dependent spontaneous release of neurotransmitter in absence of action potentials in neuronal cells. Involved both in glucose-stimulated insulin secretion in pancreatic cells and insulin-dependent GLUT4 transport to the plasma membrane in adipocytes.

Subunit / interactions. Interacts with the SNARE (soluble N-ethylmaleimide-sensitive factor attached protein receptor) complex composed of SNAP25, STX1A and VAMP2; the interaction is calcium-dependent and competitive with SYT1. Interacts with STX4; the interaction is calcium-dependent, increased by insulin and glucose, and mediates vesicle fusion with plasma membrane in pancreatic cells and adipocytes. Interacts with STXBP3; the interaction is direct, occurs at the cell membrane and regulates glucose-stimulated insulin secretion. May interact with UNC13A; the interaction mediates targeting to the plasma membrane. Interacts with cytoplasmic dynein light chain DYNLT1.

Subcellular location. Cytoplasm. Cytoplasmic granule. Cell membrane.

Tissue specificity. Widely expressed with highest levels in brain and kidney. Expressed in pancreatic islet cells (at protein level).

Domain organisation. C2 domain 1 is involved in binding calcium and phospholipids. C2 domain 2 may also play a role in the calcium-dependent targeting to membranes.

RefSeq proteins (1): NP_003576* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000008	C2_dom	Domain
IPR001565	Synaptotagmin	Domain
IPR014638	Doc2	Family
IPR035892	C2_domain_sf	Homologous_superfamily
IPR043566	Rabphilin/DOC2/Noc2	Family
IPR047022	Rabphilin_Doc2_C2A	Domain

Pfam: PF00168

UniProt features (25 total): binding site 12, region of interest 4, compositionally biased region 3, domain 2, chain 1, modified residue 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14184-F1	79.21	0.61

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (12): 157; 163; 218; 220; 297; 297; 303; 357; 357; 359; 359; 365

Post-translational modifications (1): 411

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 150 (showing top): RNGTGGGC_UNKNOWN, GOBP_REGULATION_OF_VESICLE_FUSION, GOBP_POSITIVE_REGULATION_OF_CALCIUM_ION_DEPENDENT_EXOCYTOSIS, PEREZ_TP63_TARGETS, GOBP_VESICLE_ORGANIZATION, GCANCTGNY_MYOD_Q6, GOBP_INSULIN_SECRETION, GOBP_MEMBRANE_FUSION, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_REGULATION_OF_EXOCYTOSIS, GOBP_REGULATION_OF_HORMONE_LEVELS, GOBP_NEUROTRANSMITTER_TRANSPORT, GOBP_HORMONE_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION

GO Biological Process (8): intracellular protein localization (GO:0008104), positive regulation of vesicle fusion (GO:0031340), positive regulation of insulin secretion (GO:0032024), positive regulation of calcium ion-dependent exocytosis (GO:0045956), calcium ion-regulated exocytosis of neurotransmitter (GO:0048791), spontaneous neurotransmitter secretion (GO:0061669), calcium-dependent activation of synaptic vesicle fusion (GO:0099502), chemical synaptic transmission (GO:0007268)

GO Molecular Function (4): calcium ion binding (GO:0005509), calcium-dependent phospholipid binding (GO:0005544), syntaxin binding (GO:0019905), metal ion binding (GO:0046872)

GO Cellular Component (6): cytoplasm (GO:0005737), plasma membrane (GO:0005886), synapse (GO:0045202), presynapse (GO:0098793), membrane (GO:0016020), SNARE complex (GO:0031201)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
calcium-ion regulated exocytosis	2
synaptic vesicle exocytosis	2
macromolecule localization	1
vesicle fusion	1
positive regulation of organelle organization	1
regulation of vesicle fusion	1
positive regulation of transport	1
insulin secretion	1
positive regulation of protein secretion	1
regulation of insulin secretion	1
positive regulation of peptide hormone secretion	1
regulation of calcium ion-dependent exocytosis	1
positive regulation of regulated secretory pathway	1
neurotransmitter secretion	1
spontaneous synaptic transmission	1
positive regulation of synaptic vesicle fusion to presynaptic active zone membrane	1
anterograde trans-synaptic signaling	1
metal ion binding	1
phospholipid binding	1
SNARE binding	1
cation binding	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
cell junction	1
synapse	1
cytoplasm	1
membrane protein complex	1

Protein interactions and networks

STRING

932 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DOC2B	UNC13B	O14795	839
DOC2B	STX4	Q12846	754
DOC2B	SNAP25	P13795	623
DOC2B	DYNLT1	P63172	593
DOC2B	VAMP2	P19065	590
DOC2B	STXBP3	O00186	579
DOC2B	KLC1	Q07866	552
DOC2B	UNC13A	Q9UPW8	530
DOC2B	STX1A	Q16623	456
DOC2B	STXBP1	P61764	449
DOC2B	VSTM2B	A6NLU5	447
DOC2B	SNAP23	O00161	446
DOC2B	LRP3	O75074	436
DOC2B	TC2N	Q8N9U0	431
DOC2B	RAB13	P51153	423

IntAct

8 interactions, top by confidence:

A	B	Type	Score
DOC2A	DOC2B	psi-mi:“MI:0914”(association)	0.530
Dlg4	DOC2B	psi-mi:“MI:0407”(direct interaction)	0.440
RPH3A	RAB27A	psi-mi:“MI:0914”(association)	0.350
DOC2B	POTEF	psi-mi:“MI:0914”(association)	0.350
DOC2A	MVK	psi-mi:“MI:0914”(association)	0.350

BioGRID (9): DOC2B (Affinity Capture-MS), DOC2B (Affinity Capture-MS), DOC2B (Affinity Capture-MS), DOC2B (Affinity Capture-MS), POTEF (Affinity Capture-MS), UNC13B (Affinity Capture-MS), CHRNA3 (Affinity Capture-MS), RBM8A (Affinity Capture-MS), DOC2B (Affinity Capture-MS)

ESM2 similar proteins: A0A075F932, A8KBH6, F1LM93, K8FE10, O08625, O08835, P04409, P05126, P05130, P05696, P05771, P05772, P10102, P13217, P17252, P20444, P21521, P21579, P21707, P24505, P24506, P24507, P25455, P29101, P34693, P40749, P41823, P46096, P46097, P47191, P47861, P48018, P50232, P68403, P68404, P70169, P70610, P90980, Q14184, Q5FWL4

Diamond homologs: A0A075F932, A0FGR8, A4IJ05, K8FE10, O00445, O00750, O08625, O08835, O35681, O43581, P04409, P05128, P05129, P05130, P05696, P10102, P10829, P13677, P17252, P20444, P21521, P21579, P21707, P24505, P24506, P24507, P29101, P34693, P40748, P40749, P41823, P41885, P46096, P46097, P47191, P47708, P47709, P47861, P48018, P50232

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

68 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	59
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1353 predictions. Top by Δscore:

Variant	Effect	Δscore
17:162076:CCCA:C	donor_gain	1.0000
17:162077:CCAC:C	donor_loss	1.0000
17:162079:A:AC	donor_gain	1.0000
17:162080:C:CC	donor_gain	1.0000
17:162186:TTTGC:T	acceptor_gain	1.0000
17:162187:TTGC:T	acceptor_gain	1.0000
17:162188:TGC:T	acceptor_gain	1.0000
17:162189:GC:G	acceptor_gain	1.0000
17:162189:GCC:G	acceptor_loss	1.0000
17:162190:CC:C	acceptor_gain	1.0000
17:162191:C:CC	acceptor_gain	1.0000
17:162191:CTGGA:C	acceptor_loss	1.0000
17:164127:CA:C	donor_loss	1.0000
17:164129:C:CT	donor_loss	1.0000
17:164129:CCTTA:C	donor_gain	1.0000
17:164133:A:AC	donor_gain	1.0000
17:164134:C:CC	donor_gain	1.0000
17:164134:CTGG:C	donor_gain	1.0000
17:164202:GCCC:G	acceptor_loss	1.0000
17:164203:CC:C	acceptor_gain	1.0000
17:164204:CC:C	acceptor_gain	1.0000
17:164205:C:CC	acceptor_gain	1.0000
17:164205:C:G	acceptor_loss	1.0000
17:164206:T:A	acceptor_loss	1.0000
17:181105:A:AC	donor_gain	1.0000
17:181106:C:CC	donor_gain	1.0000
17:156376:ACCTG:A	acceptor_loss	0.9900
17:156377:CCTG:C	acceptor_loss	0.9900
17:156378:C:A	acceptor_loss	0.9900
17:156378:C:CC	acceptor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000135970 (17:179781 C>T), RS1000212080 (17:145640 G>A), RS1000388261 (17:150024 T>G), RS1000419405 (17:149758 G>A), RS1000426774 (17:175953 G>C), RS1000455711 (17:154841 T>G), RS1000464153 (17:180958 G>A,C,T), RS1000587413 (17:146453 C>A,T), RS1000647491 (17:145467 G>A), RS1000760922 (17:150960 C>G), RS1000961192 (17:146677 G>A), RS1001026541 (17:174634 G>C), RS1001084255 (17:158869 AC>A), RS1001124384 (17:163986 C>T), RS1001141364 (17:153283 G>A)

Disease associations

OMIM: gene MIM:604568 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): primary ovarian failure (MONDO:0005387), intellectual disability (MONDO:0001071)

Orphanet (2): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases methylation	2
sotorasib	affects cotreatment, decreases expression	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
benzo(e)pyrene	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, increases expression	1
pinostrobin	increases phosphorylation	1
nutlin 3	affects cotreatment, increases expression	1
trametinib	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
NVP-BKM120	decreases expression, affects cotreatment	1
Resveratrol	affects cotreatment, decreases expression	1
Copper	affects cotreatment, decreases expression	1
Dactinomycin	increases expression, affects cotreatment	1
Diethylhexyl Phthalate	decreases expression	1
Lead	affects expression	1
Lipopolysaccharides	decreases reaction, increases expression	1
Malathion	decreases expression	1
Methapyrilene	increases methylation	1
Oxygen	increases expression	1
Rotenone	increases expression	1
Tetrachlorodibenzodioxin	decreases expression	1
Triclosan	increases expression	1
1-Methyl-4-phenylpyridinium	increases expression	1

Clinical trials (associated diseases)

272 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF